Short Interest in Cellectar Biosciences, Inc. (NASDAQ:CLRB) Drops By 66.8%

Posted by Brian Himes on Jun 14th, 2026

Cellectar Biosciences, Inc. (NASDAQ:CLRB – Get Free Report) was the target of a large decline in short interest in May. As of May 29th, there was short interest totaling 258,202 shares, a decline of 66.8% from the May 14th total of 777,622 shares. Approximately 3.3% of the shares of the stock are short sold. Based on an average trading volume of 236,060 shares, the days-to-cover ratio is presently 1.1 days.

Cellectar Biosciences Stock Down 0.9%

CLRB stock traded down $0.02 during trading on Friday, hitting $2.23. The company had a trading volume of 66,121 shares, compared to its average volume of 192,184. The firm has a 50-day moving average price of $2.86 and a 200-day moving average price of $3.10. Cellectar Biosciences has a 12 month low of $2.20 and a 12 month high of $13.47. The stock has a market cap of $17.82 million, a price-to-earnings ratio of -0.33 and a beta of 0.52.

Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) last posted its quarterly earnings data on Thursday, May 14th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, topping the consensus estimate of ($1.88) by $0.55. Equities analysts expect that Cellectar Biosciences will post -2.34 EPS for the current year.

Analysts Set New Price Targets

CLRB has been the topic of several recent analyst reports. Maxim Group raised Cellectar Biosciences from a “hold” rating to a “buy” rating in a report on Tuesday, March 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of Cellectar Biosciences in a report on Monday, April 20th. Roth Mkm reissued a “buy” rating and issued a $11.00 target price on shares of Cellectar Biosciences in a report on Tuesday, May 5th. Finally, LADENBURG THALM/SH SH initiated coverage on Cellectar Biosciences in a report on Friday, May 15th. They issued a “buy” rating on the stock. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $11.00.

Get Our Latest Stock Report on Cellectar Biosciences

Institutional Trading of Cellectar Biosciences

A number of large investors have recently made changes to their positions in CLRB. Bank of America Corp DE increased its position in shares of Cellectar Biosciences by 25.3% in the 4th quarter. Bank of America Corp DE now owns 206,783 shares of the biopharmaceutical company’s stock valued at $62,000 after buying an additional 41,704 shares in the last quarter. Dimensional Fund Advisors LP bought a new stake in shares of Cellectar Biosciences in the 3rd quarter valued at $73,000. Citadel Advisors LLC bought a new stake in shares of Cellectar Biosciences in the 3rd quarter valued at $104,000. Sequoia Financial Advisors LLC increased its position in shares of Cellectar Biosciences by 135.1% in the 4th quarter. Sequoia Financial Advisors LLC now owns 25,350 shares of the biopharmaceutical company’s stock valued at $75,000 after buying an additional 14,567 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Cellectar Biosciences by 15.0% in the 4th quarter. Geode Capital Management LLC now owns 28,636 shares of the biopharmaceutical company’s stock valued at $84,000 after buying an additional 3,744 shares in the last quarter. Institutional investors own 16.41% of the company’s stock.

About Cellectar Biosciences

(Get Free Report)

Cellectar Biosciences, Inc is a clinical‐stage biopharmaceutical company focused on the development of targeted cancer therapies and imaging agents. The company’s proprietary phospholipid drug conjugate (PDC) technology platform is designed to selectively deliver therapeutic and diagnostic payloads to malignant cells while sparing healthy tissue. Through its PDC approach, Cellectar aims to improve the efficacy and safety profile of traditional treatments like chemotherapy and radiotherapy.

Its lead therapeutic candidate, CLR 131, is a radioisotope‐labeled PDC being evaluated in Phase II clinical trials for relapsed or refractory B‐cell malignancies, including multiple myeloma and non‐Hodgkin lymphoma.